Welcome to our dedicated page for Senestech SEC filings (Ticker: SNES), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SenesTech, Inc. (NASDAQ: SNES) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. SenesTech is a biotechnology company focused on fertility control for managing rodent populations, and its filings offer detailed information on its operations, financing activities, and governance.
Key documents available through EDGAR and summarized with AI-powered insights include Form 10-K annual reports, which describe the business, risk factors, and strategy around products such as ContraPest® and the Evolve rodent birth control line, and Form 10-Q quarterly reports, which update investors on revenues, gross margins, operating expenses, and cash position. These periodic reports help readers understand how SenesTech’s fertility control products and multi-channel distribution efforts are reflected in its financial statements.
SenesTech also files numerous Form 8-K current reports documenting material events. Recent 8-K filings describe warrant inducement agreements and related financings, at-the-market offering prospectus supplements, the appointment and compensation of an interim chief operating officer, board changes, and the release of quarterly financial results. These filings provide structured detail on capital raises, equity-linked securities, and key management decisions.
Through this page, users can also review registration statements and prospectus supplements referenced in 8-Ks, which outline at-the-market equity programs and additional registered shares. Stock Titan’s tools surface new filings in real time and apply AI-generated summaries to highlight the main points of lengthy documents, helping investors quickly locate information on SenesTech’s financial condition, equity offerings, and significant corporate events without reading every page manually.
SenesTech, Inc. has filed a new prospectus supplement allowing it to offer and sell up to $7,580,675 of common stock from time to time through H.C. Wainwright & Co. under an at-the-market Sales Agreement. This capacity reflects the $10,629,569.80 limit under General Instruction I.B.6 of Form S-3, after deducting $3,048,894.72 of securities sold in the prior 12 months. As of this supplement, SenesTech had 5,185,333 shares of common stock outstanding and an aggregate market value of non-affiliate holdings of $31,888,709.40, and sales remain subject to the one-third cap while that market value is below $75,000,000.
SenesTech, Inc. filed an S-3 shelf prospectus registering shares underlying warrants and common stock for resale by selling stockholders; its common stock trades on Nasdaq under the symbol SNES. The prospectus states proceeds will not be received by the company except for cash from any warrant exercises, which the company intends to use for general corporate purposes including R&D, capital expenditures, working capital and potential acquisitions though no commitments exist.
The filing highlights the company’s rodent fertility-control products (ContraPest and Evolve), asserts beliefs about product palatability and population impacts, and warns of continued operating losses, dependence on successful commercialization and regulatory approvals, and dilution risk from outstanding warrants and potential exercises subject to beneficial ownership limits. The prospectus discloses multiple selling stockholders and related warrant mechanics and includes exhibits, legal and accounting consents, indemnification provisions and customary plan-of-distribution methods.
SenesTech, Inc. (SNES) reporting: Lynn Yako filed an Initial Statement of Beneficial Ownership (Form 3) identifying her relationship to the issuer as a Director and reporting no securities beneficially owned. The event date listed is 07/05/2025 and the form bears a signature dated 08/02/2025. The filing includes an exhibit: a Limited Power of Attorney.
SenesTech, Inc. (a Delaware corporation with principal place in Surprise, Arizona) filed a Form D disclosing a Regulation D private offering of common stock warrants that raised an aggregate of $273,539. The filing reports the total amount sold as $273,539 with $0 remaining to be sold and indicates the offering relied on Rule 506(b). Five investors participated and the issuer states $0 of the gross proceeds were used to pay named executive officers.
The placement agent disclosed is H.C. Wainwright & Co., LLC, and the filing estimates sales commissions of $474,589. It also discloses placement agent warrants to purchase up to 72,944 shares at an exercise price of $5.4219 per share, plus accountable expenses and a management fee. The offering is not tied to a business combination and is not intended to last more than one year.
PFS Cap Mgt Co and PFS Trust report beneficial ownership of 340,000 shares of SenesTech, Inc., representing 9.99% of the outstanding common stock based on 2,247,691 shares outstanding as of June 24, 2025, per the company's Prospectus Supplement No. 2. The reported position includes 120,000 shares issuable upon exercise of warrants held by the Trust but those warrants are subject to a 9.99% exercise blocker, so the Reporting Persons cannot currently exercise all warrants to exceed the 9.99% threshold. The filing shows shared voting and dispositive power over 340,000 shares and no sole voting or dispositive power. The Schedule 13G/A is signed by John David Kessler on August 12, 2025.